Growth hormone peptides and recovery-focused compounds represent one of the most actively researched areas in peptide science. Tesamorelin belongs to this category, with research exploring its potential effects on growth hormone signaling, tissue repair, and recovery processes.
A stabilized GHRH analog FDA-approved for HIV-associated lipodystrophy. Reduces visceral adipose tissue through physiological GH stimulation while maintaining IGF-1 within normal ranges.
Also Known As
Egrifta, TH9507
What is Tesamorelin?
Tesamorelin is classified under the GH / Recovery category of peptides. A stabilized GHRH analog FDA-approved for HIV-associated lipodystrophy. Reduces visceral adipose tissue through physiological GH stimulation while maintaining IGF-1 within normal ranges.
Mechanism of Action: A synthetic analog of GHRH with a trans-3-hexenoic acid modification that enhances stability. It stimulates pulsatile GH release from the pituitary, increasing lipolysis particularly in visceral adipose tissue, while preserving the hypothalamic-pituitary feedback mechanism.
Growth Hormone & Recovery Research
Primary Research Areas: HIV-associated lipodystrophy, visceral adipose tissue reduction, cognitive function in aging, NASH, metabolic syndrome.
Key Research Findings: FDA-approved for HIV-associated lipodystrophy. Clinical trials showed significant reduction in visceral adipose tissue without affecting subcutaneous fat. Emerging research shows improvements in cognitive function in elderly adults and potential NASH benefits.
Safety Profile & Considerations
FDA-approved with well-characterized safety profile. May cause injection site reactions, arthralgias, and fluid retention. Monitoring of IGF-1 levels is recommended. Contraindicated in active malignancy.
Related Research Topics
Understanding Tesamorelin requires familiarity with these related concepts in gh / recovery research. Each topic represents a broader field that intersects with current peptide research.
References & Further Reading
Falutz J, et al. Effects of tesamorelin on body composition and metabolic parameters. J Clin Endocrinol Metab. 2007;92(8):3210-17.
Stay Updated on Peptide Research
Get the latest science-backed articles on peptides delivered to your inbox.